Maintenance of Certification – Hematology.org
Maintenance of Certification
Related Articles
Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.
FDA Accepts BLA for Belantamab Mafodotin Combinations in R/R Multiple Myeloma
The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported…
FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma
The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
FDA Approves HER2 Test as Companion Diagnostic for Zanidatamab in Biliary Tract Cancer
The FDA approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.
ASH Annual Meeting Abstracts
Late-breaking abstracts feature substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at…
Ane Gerda Eriksson (@agerikssonmd.bsky.social)
👩🏼⚕️🇳🇴🏥Gyn Oncologist at The Norwegian Radium Hospital, Oslo University Hospital ESGO council @oncoalert faculty
Pharmacological blockade of a pioneer transcription factor
Abstract. Cancers frequently co-opt lineage-specific transcription factors (TFs) utilized in normal development to sustain proliferation. However, the effects of these TFs on tumor development depend…
Data for NVL-655 in Advanced ALK+ NSCLC and Solid Tumors from the ALKOVE-1 Trial
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Program
Program details for the 13th AACR-JCA Joint Conference: From Cancer Discovery Science to Therapeutic Innovation
